{"id":30070,"date":"2025-02-19T15:23:13","date_gmt":"2025-02-19T14:23:13","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=30070"},"modified":"2025-03-03T14:12:30","modified_gmt":"2025-03-03T13:12:30","slug":"leurope-unie-dans-la-lutte-contre-lantibioresistance","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/","title":{"rendered":"L\u2019Europe unie dans la lutte contre l\u2019antibior\u00e9sistance."},"content":{"rendered":"\n<p>La r\u00e9sistance aux antibiotiques (RAM) est aujourd\u2019hui l\u2019un des enjeux majeurs en Sant\u00e9 Publique \u00e0 l\u2019\u00e9chelle mondiale. Les antibiotiques, indispensables \u00e0 la m\u00e9decine moderne, permettent de traiter et pr\u00e9venir de nombreuses infections, notamment lors de chirurgies, de greffes ou de chimioth\u00e9rapies.<\/p>\n\n\n\n<p><strong>Pourtant ces pr\u00e9cieuses mol\u00e9cules sont aujourd\u2019hui menac\u00e9es alors que de plus en plus de bact\u00e9ries d\u00e9veloppent des r\u00e9sistances et que de moins en moins d\u2019antibiotiques innovants sont mis sur le march\u00e9.<\/strong><\/p>\n\n\n\n<p>Chaque ann\u00e9e l\u2019antibior\u00e9sistance serait responsable de 1,1 \u00e0 1,3 millions de d\u00e9c\u00e8s dans le monde d\u2019apr\u00e8s des chiffres de 2019 <sup>1<\/sup> et 2021 <sup>2<\/sup> dont 33 000 en Europe <sup>3<\/sup>.<\/p>\n\n\n\n<p><strong>Entre 2025 et 2050, ce sont 39 millions de personnes qui pourraient d\u00e9c\u00e9der des suites d\u2019une infection bact\u00e9rienne r\u00e9sistante aux antibiotiques <sup>2<\/sup>.<\/strong><\/p>\n\n\n\n<p>En Europe, la RAM entra\u00eene 2,5 millions de jours d\u2019hospitalisation suppl\u00e9mentaires et co\u00fbte 1,5 milliard d\u2019euros par an <sup>4<\/sup>. Elle a aussi des cons\u00e9quences sur les rendements agricoles avec une augmentation de la mortalit\u00e9 des animaux de rente et une perte \u00e9conomique \u00e9valu\u00e9e \u00e0 13 milliards de dollars chaque ann\u00e9e <sup>5<\/sup>.<\/p>\n\n\n\n<p>Le ph\u00e9nom\u00e8ne de la RAM est complexe et difficile \u00e0 enrayer. En effet, les bact\u00e9ries d\u00e9veloppent des r\u00e9sistances qu\u2019elles peuvent transmettre \u00e0 d\u2019autres bact\u00e9ries. Cette propagation de la r\u00e9sistance est notamment amplifi\u00e9e par la sur-utilisation des antibiotiques. Par ailleurs, les bact\u00e9ries circulent facilement d\u2019un pays \u00e0 l\u2019autre via les flux touristiques et commerciaux, et la r\u00e9sistance concerne aussi bien le secteur humain qu\u2019animal ainsi que l\u2019environnement. La RAM a donc une dimension globale.<\/p>\n\n\n\n<p><strong>Pour faire face, il convient donc d\u2019adopter une approche holistique s\u2019attaquant au probl\u00e8me dans toutes ses dimensions (humaine\/animale\/environnementale)&nbsp;: une approche dite \u00ab&nbsp;One Health&nbsp;\u00bb ou \u00ab&nbsp;Une Seule Sant\u00e9&nbsp;\u00bb.<\/strong><\/p>\n\n\n\n<p>Depuis 2015 et la publication d\u2019un plan d\u2019action global par l\u2019Organisation Mondiale de la Sant\u00e9 (OMS)<sup> 8<\/sup>, les diff\u00e9rents pays et organisations internationales ont pris conscience de la n\u00e9cessit\u00e9 de s\u2019organiser pour \u00e9tablir ensemble des feuilles de route pour r\u00e9duire le fl\u00e9au de l\u2019antibior\u00e9sistance. De plus, la n\u00e9cessit\u00e9 d\u2019une coordination \u00ab&nbsp;One Health&nbsp;\u00bb a conduit 4 organisations internationales (OMS, organisation mondiale pour la sant\u00e9 animale OMSA, l\u2019Organisation des Nations unies pour l&#8217;alimentation et l&#8217;agriculture FAO et le Programme des Nations unies pour l&#8217;environnement UNEP) \u00e0 se regrouper sous l\u2019appellation \u00ab&nbsp;Quadripartite&nbsp;\u00bb pour \u00e9tablir des plans d\u2019action conjoints.<\/p>\n\n\n\n<p><strong>L\u2019Europe a rapidement suivi ce mouvement et, en 2017, la Commission Europ\u00e9enne a adopt\u00e9 un plan d\u2019action \u00ab Une Seule Sant\u00e9 \u00bb pour faire de l\u2019Europe un mod\u00e8le de bonnes pratiques en mati\u00e8re de lutte contre la RAM <sup>6<\/sup>.<\/strong><\/p>\n\n\n\n<p>Ce plan couvre les 3 sant\u00e9s (humaine\/animale et environnement) et s\u2019articule autour de sept axes :<\/p>\n\n\n\n<ul>\n<li>Bon usage des antibiotiques,<\/li>\n\n\n\n<li>Pr\u00e9vention des infections,<\/li>\n\n\n\n<li>Surveillance,<\/li>\n\n\n\n<li>Sensibilisation,<\/li>\n\n\n\n<li>Recherche,<\/li>\n\n\n\n<li>Engagement politique<\/li>\n\n\n\n<li>Et coop\u00e9ration internationale.<\/li>\n<\/ul>\n\n\n\n<p>En 2023, l\u2019Europe est all\u00e9e plus loin et a fix\u00e9 des objectifs \u00e0 atteindre \u00e0 l\u2019horizon 2030 dans tous les \u00e9tats membres et a propos\u00e9 des actions pour y parvenir <sup>7<\/sup>. Parmi ces objectifs :<\/p>\n\n\n\n<p><strong>Une r\u00e9duction de 20 % de la consommation humaine totale d\u2019antibiotiques et une r\u00e9duction de 50 % des ventes globales dans l\u2019UE d\u2019antimicrobiens utilis\u00e9s pour les animaux de ferme et l\u2019aquaculture.<\/strong><\/p>\n\n\n\n<p>En 2024, les Nations Unies ont renforc\u00e9 cet engagement mondial via une d\u00e9claration d\u2019actions approuv\u00e9e par les diff\u00e9rents pays pour r\u00e9duire la mortalit\u00e9 due \u00e0 la RAM de 10% d\u2019ici 2030.<\/p>\n\n\n\n<p><strong>Pour traduire ses engagements en actions concr\u00e8tes et aider les \u00e9tat membres \u00e0 renforcer leurs politiques de sant\u00e9 publique en mati\u00e8re de lutte contre la RAM, la Commission Europ\u00e9enne a financ\u00e9, entre autres, deux <a href=\"https:\/\/eu-jamrai.eu\/\">actions conjointes Europ\u00e9enne pour lutter contre la RAM et les infections associ\u00e9es aux soins<\/a>, appel\u00e9es EU-JAMRAI.<\/strong><\/p>\n\n\n\n<p>La premi\u00e8re action conjointe, <strong>EU-JAMRAI 1<\/strong> (2017-2021), financ\u00e9e \u00e0 hauteur de 4 millions d\u2019euros, r\u00e9unissait 44 partenaires (minist\u00e8res, agences de sant\u00e9 publique, instituts de recherches, h\u00f4pitaux\u2026) issus de 26 pays. Ce projet pilot\u00e9 par la France, via l\u2019<a href=\"https:\/\/www.inserm.fr\/\">Inserm<\/a> (Institut national de la sant\u00e9 et de la recherche m\u00e9dicale), avait pour ambition de coordonner une r\u00e9ponse unifi\u00e9e \u00e0 la RAM en Europe et de cod\u00e9velopper des politiques de sant\u00e9 publique et outils pour y r\u00e9pondre. Ce programme collaboratif a permis aux diff\u00e9rents pays impliqu\u00e9s d\u2019\u00e9changer sur leurs pratiques et a donn\u00e9 lieu \u00e0 diff\u00e9rentes notes d&#8217;orientation visant \u00e0 informer les d\u00e9cideurs politiques europ\u00e9ens des besoins qui restaient \u00e0 combler avec la mise en place d\u2019outils de structuration et de formation.<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-1 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<p>Dans ce sens, la EU-JAMRAI 1 a initi\u00e9 un programme europ\u00e9en de surveillance de la r\u00e9sistance chez les animaux malades, EARS-Vet, sur le mod\u00e8le du programme en sant\u00e9 humain, EARS-Net coordonn\u00e9 par l\u2019agence europ\u00e9enne pour le contr\u00f4le et la pr\u00e9vention des infections, ECDC <sup>9<\/sup>. De plus, la EU-JAMRAI 1 a d\u00e9velopp\u00e9 un plan de sensibilisation du grand public via un jeu en ligne pour sensibiliser aux maladies infectieuses et \u00e0 leur pr\u00e9vention, des campagnes de communication sur les r\u00e9seaux sociaux ou le d\u00e9veloppement d\u2019un symbole pour repr\u00e9senter la probl\u00e9matique de la RAM.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large is-resized\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"531\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Antibiorestance-symbole-AMR-1024x531.png\" alt=\"\" class=\"wp-image-30104\" style=\"width:771px;height:auto\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Antibiorestance-symbole-AMR-1024x531.png 1024w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Antibiorestance-symbole-AMR-300x156.png 300w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Antibiorestance-symbole-AMR-768x398.png 768w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Antibiorestance-symbole-AMR-1536x796.png 1536w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Antibiorestance-symbole-AMR-2048x1062.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><\/div><\/div>\n<\/div>\n\n\n\n<p>Suite \u00e0 cette premi\u00e8re \u00e9dition r\u00e9ussie, la Commission Europ\u00e9enne a lanc\u00e9 une seconde action conjointe baptis\u00e9e <strong>EU-JAMRAI 2<\/strong> (2024-2027). &nbsp;Financ\u00e9e \u00e0 hauteur de 50 millions d\u2019euros, et toujours port\u00e9e par la France, via l\u2019Inserm, cette seconde \u00e9dition du projet r\u00e9unit d\u00e9sormais 128 partenaires issus de 30 pays, incluant les 27 \u00c9tats membres de l\u2019Union Europ\u00e9enne, ainsi que la Norv\u00e8ge, l\u2019Islande et l\u2019Ukraine. Dans la continuit\u00e9 du projet EU-JAMRAI 1, les axes de travail principaux sont le bon usage des antibiotiques, la pr\u00e9vention des infections, la surveillance de la r\u00e9sistance, l\u2019am\u00e9lioration de l\u2019acc\u00e8s aux traitements, et la sensibilisation \u2013 tout en int\u00e9grant davantage l\u2019approche \u00ab Une Seule Sant\u00e9 \u00bb avec des activit\u00e9s ciblant les 3 sant\u00e9s.<\/p>\n\n\n\n<p>Le projet met ainsi en \u0153uvre des activit\u00e9s transversales, comme le d\u00e9veloppement d\u2019une surveillance int\u00e9gr\u00e9e \u00ab Une Seule Sant\u00e9 \u00bb \u00e0 l\u2019\u00e9chelle europ\u00e9enne d\u00e9finissant des indicateurs permettant de suivre l\u2019\u00e9volution de la r\u00e9sistance aux antibiotiques dans les 3 secteurs, humain, animal et environnemental. Le projet EU-JAMRAI 2 mettra aussi l\u2019accent sur la formation et le renforcement des capacit\u00e9s tant pour les professionnels que pour les d\u00e9cideurs politiques, avec des mesures visant \u00e0 soutenir les efforts nationaux. L\u2019un des principaux d\u00e9fis de l\u2019action conjointe sera d\u2019assurer l\u2019engagement politique continu des pays participants pendant et apr\u00e8s le projet.<\/p>\n\n\n\n<p>\u00c0 cette fin, le projet s\u2019appuiera sur un r\u00e9seau europ\u00e9en de d\u00e9cideurs politiques, incluant au moins un repr\u00e9sentant par pays participant. Ce r\u00e9seau permettra de renforcer la coop\u00e9ration entre les pays, de faciliter l\u2019\u00e9change de bonnes pratiques et d\u2019identifier les besoins sp\u00e9cifiques de chaque pays en mati\u00e8re de lutte contre la RAM, afin d\u2019y apporter des r\u00e9ponses adapt\u00e9es.<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-2 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"EU-JAMRAI 2 - The Power of being ONE (1 Min)\" width=\"640\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/gTKiAsvPQ7k?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n<\/div>\n<\/div>\n\n\n\n<p><strong>A travers le projet EU-JAMRAI 2, l\u2019Europe s\u2019engage donc dans cette dynamique mondiale d\u2019une d\u00e9marche coordonn\u00e9e \u00ab&nbsp;Une Seule Sant\u00e9&nbsp;\u00bb, en appui aux efforts nationaux de d\u00e9veloppement de plans d\u2019actions de lutte contre la RAM dans tous les pays.<\/strong><\/p>\n\n\n\n<p>Via ses ambitions, le projet EU-JAMRAI 2 dessine un avenir o\u00f9 les pays europ\u00e9ens partageront activement leurs bonnes pratiques en mati\u00e8re de lutte contre la RAM, o\u00f9 les professionnels de sant\u00e9 seront form\u00e9s aux meilleurs standards de soin, o\u00f9 les patients auront acc\u00e8s \u00e0 des traitements appropri\u00e9s et o\u00f9 les citoyens seront sensibilis\u00e9s \u00e0 la n\u00e9cessit\u00e9 cruciale de pr\u00e9server l\u2019efficacit\u00e9 des antibiotiques.<\/p>\n\n\n\n<p><strong>Mais alors, l\u2019Europe parviendra-t-elle \u00e0 atteindre son ambition d\u2019\u00eatre un mod\u00e8le de bonnes pratiques en mati\u00e8re de lutte contre la RAM&nbsp;? R\u00e9ponse fin 2027 \u00e0 la fin du projet EU-JAMRAI 2.<\/strong><\/p>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p style=\"font-size:25px\"><em><strong>R\u00e9f\u00e9rences&nbsp;:<\/strong><\/em><\/p>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><em><sup>1<\/sup><\/em><em> Murray et al., Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, Volume 399, Issue 10325, 629 &#8211; 655<\/em><\/p>\n\n\n\n<p><em><sup>2<\/sup><\/em><em> Naghavi et al., Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. The Lancet, Volume 404, Issue 10459, 1199 \u2013 1226<\/em><\/p>\n\n\n\n<p><em><sup>3<\/sup><\/em><em> Cassini et al., Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019 Jan;19(1):56-66.<\/em><\/p>\n\n\n\n<p><em><sup>4<\/sup><\/em><em> ECDC, The bacterial challenge: time to react &#8211; A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. 2009<\/em><\/p>\n\n\n\n<p><em><sup>5<\/sup><\/em><em> UNEP, Bracing for Superbugs: Strengthening environmental action in the One Health response to antimicrobial resistance. 2023. <\/em><a href=\"https:\/\/www.unep.org\/resources\/superbugs\/environmental-action\"><em>https:\/\/www.unep.org\/resources\/superbugs\/environmental-action<\/em><\/a><em><\/em><\/p>\n\n\n\n<p><em><sup>6<\/sup><\/em><em> A European One Health Action Plan against Antimicrobial Resistance (AMR). 2017. <\/em><a href=\"https:\/\/health.ec.europa.eu\/document\/download\/353f40d1-f114-4c41-9755-c7e3f1da5378_fr?filename=amr_2017_action-plan.pdf\"><em>https:\/\/health.ec.europa.eu\/document\/download\/353f40d1-f114-4c41-9755-c7e3f1da5378_fr?filename=amr_2017_action-plan.pdf<\/em><\/a><em><\/em><\/p>\n\n\n\n<p><em><sup>7<\/sup><\/em><em> Council Recommendation on stepping up EU actions to combat antimicrobial resistance in a One Health approach. 2023. <\/em><a href=\"https:\/\/health.ec.europa.eu\/publications\/council-recommendation-stepping-eu-actions-combat-antimicrobial-resistance-one-health-approach_en?prefLang=fr\"><em>https:\/\/health.ec.europa.eu\/publications\/council-recommendation-stepping-eu-actions-combat-antimicrobial-resistance-one-health-approach_en?prefLang=fr<\/em><\/a><em><\/em><\/p>\n\n\n\n<p><em><sup>8<\/sup><\/em><em> Global action plan on antimicrobial resistance. 2015. <\/em><a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789241509763\"><em>https:\/\/www.who.int\/publications\/i\/item\/9789241509763<\/em><\/a><em><\/em><\/p>\n\n\n\n<p><em><sup>9<\/sup><\/em><em> R\u00e9seau de surveillance europen EARS-Net, <\/em><a href=\"https:\/\/www.ecdc.europa.eu\/en\/about-us\/networks\/disease-networks-and-laboratory-networks\/ears-net-data\"><em>https:\/\/www.ecdc.europa.eu\/en\/about-us\/networks\/disease-networks-and-laboratory-networks\/ears-net-data<\/em><\/a><\/p>\n\n\n\n<div style=\"height:34px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p style=\"font-size:25px\"><strong>Auteur et autrices<\/strong><\/p>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-3 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><div class=\"wp-block-image is-style-rounded\">\n<figure class=\"aligncenter size-medium is-resized\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Yohann-Lacotte-1-300x300.jpg\" alt=\"\" class=\"wp-image-30075\" style=\"width:219px;height:auto\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Yohann-Lacotte-1-300x300.jpg 300w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Yohann-Lacotte-1-150x150.jpg 150w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Yohann-Lacotte-1-768x768.jpg 768w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Yohann-Lacotte-1.jpg 800w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/figure><\/div>\n\n\n<p class=\"has-text-align-center has-small-font-size\">Yohann Lacotte<\/p>\n\n\n\n<p class=\"has-text-align-center has-small-font-size\">Chef de projet<br>PROMISE<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><div class=\"wp-block-image is-style-rounded\">\n<figure class=\"aligncenter size-full is-resized\"><img decoding=\"async\" width=\"800\" height=\"800\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Evelyne-Jouvin-Marche-1.png\" alt=\"\" class=\"wp-image-30077\" style=\"width:218px;height:auto\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Evelyne-Jouvin-Marche-1.png 800w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Evelyne-Jouvin-Marche-1-300x300.png 300w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Evelyne-Jouvin-Marche-1-150x150.png 150w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Evelyne-Jouvin-Marche-1-768x768.png 768w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/><\/figure><\/div>\n\n\n<p class=\"has-text-align-center has-small-font-size\">Evelyne Jouvin-Marche<\/p>\n\n\n\n<p class=\"has-text-align-center has-small-font-size\">Coordinatrice<br>scientifique du<br>PPR Antibior\u00e9sistance<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><div class=\"wp-block-image is-style-rounded\">\n<figure class=\"aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"800\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Marie-Cecile-Ploy.png\" alt=\"\" class=\"wp-image-30079\" style=\"width:218px;height:auto\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Marie-Cecile-Ploy.png 800w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Marie-Cecile-Ploy-300x300.png 300w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Marie-Cecile-Ploy-150x150.png 150w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Marie-Cecile-Ploy-768x768.png 768w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/><\/figure><\/div>\n\n\n<p class=\"has-text-align-center has-small-font-size\">Marie-C\u00e9cile Ploy<\/p>\n\n\n\n<p class=\"has-text-align-center has-small-font-size\">Professeure de<br>microbiologie<\/p>\n<\/div>\n<\/div>\n\n\n\n<p class=\"has-small-font-size\">1&nbsp;: Universit\u00e9 de Limoges, Inserm, CHU Limoges, RESINFIT, U 1092, 87000 Limoges, France<\/p>\n\n\n\n<p class=\"has-small-font-size\">2&nbsp;: Inserm, Institut th\u00e9matique Physiopathologie, M\u00e9tabolisme, Nutrition (PMN), 75013 Paris, France<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La r\u00e9sistance aux antibiotiques est aujourd\u2019hui l\u2019un des enjeux majeurs en Sant\u00e9 Publique \u00e0 l\u2019\u00e9chelle mondiale. Les antibiotiques, indispensables \u00e0 la m\u00e9decine moderne, permettent de traiter et pr\u00e9venir de nombreuses infections, notamment lors de chirurgies, de greffes ou de chimioth\u00e9rapies. Pourtant ces pr\u00e9cieuses mol\u00e9cules sont aujourd\u2019hui menac\u00e9es alors que de plus en plus de bact\u00e9ries d\u00e9veloppent des r\u00e9sistances et que de moins en moins d\u2019antibiotiques innovants sont mis sur le march\u00e9.<\/p>\n","protected":false},"author":275,"featured_media":30113,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[3341],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>L\u2019Europe unie dans la lutte contre l\u2019antibior\u00e9sistance. - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L\u2019Europe unie dans la lutte contre l\u2019antibior\u00e9sistance. - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-19T14:23:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-03T13:12:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Europe-flag-copie-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"974\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"supportmlcom\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"supportmlcom\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/\"},\"author\":{\"name\":\"supportmlcom\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/126addd59310b0af2dd75ae8223445a5\"},\"headline\":\"L\u2019Europe unie dans la lutte contre l\u2019antibior\u00e9sistance.\",\"datePublished\":\"2025-02-19T14:23:13+00:00\",\"dateModified\":\"2025-03-03T13:12:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/\"},\"wordCount\":1603,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Europe-flag-copie-scaled.jpg\",\"articleSection\":[\"Editoriaux\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/\",\"name\":\"L\u2019Europe unie dans la lutte contre l\u2019antibior\u00e9sistance. - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Europe-flag-copie-scaled.jpg\",\"datePublished\":\"2025-02-19T14:23:13+00:00\",\"dateModified\":\"2025-03-03T13:12:30+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Europe-flag-copie-scaled.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Europe-flag-copie-scaled.jpg\",\"width\":2560,\"height\":974},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Editoriaux\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"L\u2019Europe unie dans la lutte contre l\u2019antibior\u00e9sistance.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/126addd59310b0af2dd75ae8223445a5\",\"name\":\"supportmlcom\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L\u2019Europe unie dans la lutte contre l\u2019antibior\u00e9sistance. - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/","og_locale":"fr_FR","og_type":"article","og_title":"L\u2019Europe unie dans la lutte contre l\u2019antibior\u00e9sistance. - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2025-02-19T14:23:13+00:00","article_modified_time":"2025-03-03T13:12:30+00:00","og_image":[{"width":2560,"height":974,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Europe-flag-copie-scaled.jpg","type":"image\/jpeg"}],"author":"supportmlcom","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"supportmlcom","Dur\u00e9e de lecture estim\u00e9e":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/"},"author":{"name":"supportmlcom","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/126addd59310b0af2dd75ae8223445a5"},"headline":"L\u2019Europe unie dans la lutte contre l\u2019antibior\u00e9sistance.","datePublished":"2025-02-19T14:23:13+00:00","dateModified":"2025-03-03T13:12:30+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/"},"wordCount":1603,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Europe-flag-copie-scaled.jpg","articleSection":["Editoriaux"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/","name":"L\u2019Europe unie dans la lutte contre l\u2019antibior\u00e9sistance. - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Europe-flag-copie-scaled.jpg","datePublished":"2025-02-19T14:23:13+00:00","dateModified":"2025-03-03T13:12:30+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Europe-flag-copie-scaled.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/02\/Europe-flag-copie-scaled.jpg","width":2560,"height":974},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/leurope-unie-dans-la-lutte-contre-lantibioresistance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Editoriaux","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/"},{"@type":"ListItem","position":3,"name":"L\u2019Europe unie dans la lutte contre l\u2019antibior\u00e9sistance."}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/126addd59310b0af2dd75ae8223445a5","name":"supportmlcom"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-10 22:03:59","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/30070"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/275"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=30070"}],"version-history":[{"count":15,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/30070\/revisions"}],"predecessor-version":[{"id":30169,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/30070\/revisions\/30169"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/30113"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=30070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=30070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=30070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}